entinostat has been researched along with Benign Neoplasms in 42 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entinostat is a well-tolerated HDACi that demonstrates promising therapeutic potential in both solid and hematologic malignancies." | 8.87 | Entinostat for treatment of solid tumors and hematologic malignancies. ( Gore, L; Knipstein, J, 2011) |
| "Entinostat is a well-tolerated HDACi that demonstrates promising therapeutic potential in both solid and hematologic malignancies." | 4.87 | Entinostat for treatment of solid tumors and hematologic malignancies. ( Gore, L; Knipstein, J, 2011) |
| "Entinostat was given orally once every 2 weeks, starting at a dose of 4 mg and escalating to 6 and 10 mg every 2 weeks." | 2.80 | A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. ( Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y, 2015) |
| "Entinostat dose was escalated by 1 mg m(-2) increments." | 2.77 | Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. ( Altiok, S; Carducci, MA; Pili, R; Qian, D; Rudek, MA; Salumbides, B; Zhao, M; Zwiebel, J, 2012) |
| " Pharmacokinetic variables revealed dose-dependent and dose-proportional increases." | 2.73 | A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. ( Coffin, D; Eckhardt, SG; Gore, L; McCoy, C; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Scholz, C; Schott, A; Schultz, MK, 2008) |
| "Patients with refractory solid tumors and lymphoid malignancies were treated with oral MS-275 on a once weekly schedule for 4 weeks of a 6-week cycle." | 2.73 | Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. ( Chen, A; Chung, EJ; Conley, B; Donovan, E; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, M; Hwang, K; Kalnitskiy, M; Kummar, S; Lee, MJ; Maynard, K; Melillo, G; Murgo, AJ; Ryan, QC; Trepel, JB; Zwiebel, J, 2007) |
| " In vivo pharmacokinetic data were obtained from 64 adult patients (36 male/28 female; median age, 57 years) receiving MS-275 orally (dose range, 2 to 12 mg/m2)." | 2.72 | Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. ( Acharya, MR; Figg, WD; Gojo, I; Hwang, K; Karp, JE; Ryan, Q; Sausville, EA; Sparreboom, A; Venitz, J, 2006) |
| "The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275." | 2.71 | Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. ( Acharya, M; Chung, EJ; Elsayed, Y; Figg, WD; Headlee, D; Hwang, K; Kalnitskiy, M; Melillo, G; Monga, M; Murgo, A; Ryan, QC; Sausville, EA; Sparreboom, A; Trepel, JB; Ye, J; Zwiebel, J, 2005) |
| "Cancer cachexia is mainly characterized by wasting of skeletal muscles and fat and body weight loss, along with severe complications of major organs like liver, heart, brain and bone." | 1.72 | Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia. ( Bora, V; Goyal, RK; Johar, K; Patel, BM; Patel, D, 2022) |
| "Oncofetal protein SALL4 is critical for cancer cell survival." | 1.62 | Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy. ( Chai, L; Chen, Z; Gao, C; Kong, NR; Kumari, K; Kwon, J; Liu, M; Liu, YC; Liu, YV; Luo, H; Pimanda, JE; Qi, J; Silberstein, LE; Stein, A; Tenen, DG; Thoms, JAI; Tian, X; Unnikrishnan, A; Wong, H; Wu, Y; Xi, J; Yang, J; Yin, S, 2021) |
| "This study investigated solid cancer cell lines, which are known to be sensitive to dual PI3K and MEK inhibition but to have a limited apoptotic response." | 1.42 | Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage. ( Jokinen, E; Koivunen, JP, 2015) |
| "Therefore, we explored whether the anticancer activity of nutlin-3 could be enhanced by combination with histone deacetylase inhibitors (HDACi), i." | 1.38 | Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. ( Beck, JF; Palani, CD; Sonnemann, J, 2012) |
| "In Rhox5 highly expressed CT26 cancer cells, we observed DNA hypomethylation along with high levels of both active and repressive histone marks." | 1.37 | Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth. ( Bartlett, DL; Guo, ZS; Li, Q; O'Malley, ME, 2011) |
| "We reasoned that pretreatment of tumors with HDIs could enhance the replication and spread of OVs within malignancies." | 1.35 | Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. ( Abdelbary, H; Arguello, M; Atkins, H; Bell, JC; Bismar, TA; Breitbach, C; Diallo, JS; Falls, T; Hiscott, J; Kirn, D; Leveille, S; Nguyên, TL; Snoulten, VE; Stojdl, DF; Vähä-Koskela, MJ; Vanderhyden, BC; Werier, J; Yasmeen, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (35.71) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 11 (26.19) | 2.80 |
| Authors | Studies |
|---|---|
| Paris, M | 1 |
| Porcelloni, M | 1 |
| Binaschi, M | 1 |
| Fattori, D | 1 |
| Wong, JC | 1 |
| Guo, L | 1 |
| Peng, Z | 1 |
| Zhang, W | 2 |
| Zhang, N | 1 |
| Lai, W | 1 |
| Zhang, Z | 2 |
| Zhang, C | 1 |
| Zhang, X | 1 |
| Song, S | 1 |
| Pan, D | 1 |
| Xie, C | 1 |
| Li, J | 1 |
| Ning, Z | 1 |
| Lu, X | 1 |
| He, Y | 1 |
| Chen, L | 3 |
| Choi, SE | 1 |
| Weerasinghe, SV | 1 |
| Pflum, MK | 1 |
| Mehndiratta, S | 1 |
| Wang, RS | 1 |
| Huang, HL | 1 |
| Su, CJ | 1 |
| Hsu, CM | 1 |
| Wu, YW | 1 |
| Pan, SL | 1 |
| Liou, JP | 1 |
| Gao, S | 1 |
| Zang, J | 1 |
| Gao, Q | 1 |
| Liang, X | 1 |
| Ding, Q | 1 |
| Li, X | 1 |
| Xu, W | 1 |
| Chou, CJ | 1 |
| Zhang, Y | 1 |
| Adhikari, N | 1 |
| Amin, SA | 1 |
| Trivedi, P | 1 |
| Jha, T | 1 |
| Ghosh, B | 1 |
| Chen, J | 1 |
| Li, Y | 4 |
| Zhang, J | 1 |
| Zhang, M | 1 |
| Wei, A | 1 |
| Liu, H | 1 |
| Xie, Z | 1 |
| Ren, W | 1 |
| Duan, W | 1 |
| Shen, A | 1 |
| Hu, Y | 1 |
| Lin, S | 1 |
| Gu, Z | 1 |
| He, B | 1 |
| Yang, J | 1 |
| Gao, C | 1 |
| Liu, M | 1 |
| Liu, YC | 1 |
| Kwon, J | 1 |
| Qi, J | 1 |
| Tian, X | 1 |
| Stein, A | 1 |
| Liu, YV | 1 |
| Kong, NR | 1 |
| Wu, Y | 1 |
| Yin, S | 1 |
| Xi, J | 1 |
| Chen, Z | 1 |
| Kumari, K | 1 |
| Wong, H | 1 |
| Luo, H | 1 |
| Silberstein, LE | 1 |
| Thoms, JAI | 1 |
| Unnikrishnan, A | 1 |
| Pimanda, JE | 1 |
| Tenen, DG | 1 |
| Chai, L | 1 |
| Bora, V | 1 |
| Patel, D | 1 |
| Johar, K | 1 |
| Goyal, RK | 1 |
| Patel, BM | 1 |
| Minnar, CM | 1 |
| Chariou, PL | 1 |
| Horn, LA | 1 |
| Hicks, KC | 1 |
| Palena, C | 1 |
| Schlom, J | 1 |
| Gameiro, SR | 1 |
| Nguyen, A | 1 |
| Ho, L | 1 |
| Hogg, R | 1 |
| Walsh, SR | 1 |
| Wan, Y | 1 |
| Yan, W | 1 |
| Zou, Y | 1 |
| Zhu, R | 1 |
| Wu, T | 1 |
| Sun, X | 1 |
| Yuan, W | 1 |
| Lang, T | 1 |
| Yin, Q | 1 |
| Kiweler, N | 1 |
| Wünsch, D | 1 |
| Wirth, M | 1 |
| Mahendrarajah, N | 1 |
| Schneider, G | 1 |
| Stauber, RH | 1 |
| Brenner, W | 1 |
| Butter, F | 1 |
| Krämer, OH | 1 |
| Lu, Z | 1 |
| Zou, J | 1 |
| Li, S | 1 |
| Topper, MJ | 1 |
| Tao, Y | 1 |
| Zhang, H | 1 |
| Jiao, X | 1 |
| Xie, W | 1 |
| Kong, X | 1 |
| Vaz, M | 1 |
| Li, H | 1 |
| Cai, Y | 1 |
| Xia, L | 1 |
| Huang, P | 1 |
| Rodgers, K | 1 |
| Lee, B | 1 |
| Riemer, JB | 1 |
| Day, CP | 1 |
| Yen, RC | 1 |
| Cui, Y | 1 |
| Wang, Y | 2 |
| Easwaran, H | 1 |
| Hulbert, A | 1 |
| Kim, K | 1 |
| Juergens, RA | 1 |
| Yang, SC | 1 |
| Battafarano, RJ | 1 |
| Bush, EL | 1 |
| Broderick, SR | 1 |
| Cattaneo, SM | 1 |
| Brahmer, JR | 1 |
| Rudin, CM | 1 |
| Wrangle, J | 1 |
| Mei, Y | 1 |
| Kim, YJ | 1 |
| Zhang, B | 1 |
| Wang, KK | 1 |
| Forde, PM | 1 |
| Margolick, JB | 1 |
| Nelkin, BD | 1 |
| Zahnow, CA | 1 |
| Pardoll, DM | 1 |
| Housseau, F | 1 |
| Baylin, SB | 1 |
| Shen, L | 1 |
| Brock, MV | 1 |
| Hashimoto, A | 1 |
| Fukumoto, T | 1 |
| Zhang, R | 1 |
| Gabrilovich, D | 1 |
| Roussos Torres, ET | 1 |
| Rafie, C | 1 |
| Wang, C | 1 |
| Lim, D | 1 |
| Brufsky, A | 1 |
| LoRusso, P | 1 |
| Eder, JP | 1 |
| Chung, V | 1 |
| Downs, M | 1 |
| Geare, M | 1 |
| Piekarz, R | 1 |
| Streicher, H | 1 |
| Anforth, L | 1 |
| Rudek, MA | 3 |
| Zhu, Q | 1 |
| Besharati, S | 1 |
| Cimino-Mathews, A | 1 |
| Anders, RA | 1 |
| Stearns, V | 1 |
| Jaffee, EM | 1 |
| Connolly, RM | 1 |
| Wolfson, W | 1 |
| Oronsky, B | 1 |
| Oronsky, N | 1 |
| Knox, S | 1 |
| Fanger, G | 1 |
| Scicinski, J | 1 |
| Ngamphaiboon, N | 1 |
| Dy, GK | 1 |
| Ma, WW | 1 |
| Zhao, Y | 1 |
| Reungwetwattana, T | 1 |
| DePaolo, D | 1 |
| Ding, Y | 1 |
| Brady, W | 1 |
| Fetterly, G | 1 |
| Adjei, AA | 1 |
| Takeshima, H | 1 |
| Wakabayashi, M | 1 |
| Hattori, N | 1 |
| Yamashita, S | 1 |
| Ushijima, T | 1 |
| Jokinen, E | 1 |
| Koivunen, JP | 1 |
| Gore, L | 2 |
| Rothenberg, ML | 1 |
| O'Bryant, CL | 1 |
| Schultz, MK | 1 |
| Sandler, AB | 1 |
| Coffin, D | 1 |
| McCoy, C | 1 |
| Schott, A | 1 |
| Scholz, C | 1 |
| Eckhardt, SG | 1 |
| Di Bernardo, G | 1 |
| Squillaro, T | 1 |
| Dell'Aversana, C | 1 |
| Miceli, M | 1 |
| Cipollaro, M | 1 |
| Cascino, A | 1 |
| Altucci, L | 1 |
| Galderisi, U | 1 |
| Nguyên, TL | 1 |
| Abdelbary, H | 1 |
| Arguello, M | 1 |
| Breitbach, C | 1 |
| Leveille, S | 1 |
| Diallo, JS | 1 |
| Yasmeen, A | 1 |
| Bismar, TA | 1 |
| Kirn, D | 1 |
| Falls, T | 1 |
| Snoulten, VE | 1 |
| Vanderhyden, BC | 1 |
| Werier, J | 1 |
| Atkins, H | 1 |
| Vähä-Koskela, MJ | 1 |
| Stojdl, DF | 1 |
| Bell, JC | 1 |
| Hiscott, J | 1 |
| Häcker, S | 1 |
| Dittrich, A | 1 |
| Mohr, A | 1 |
| Schweitzer, T | 1 |
| Rutkowski, S | 1 |
| Krauss, J | 1 |
| Debatin, KM | 1 |
| Fulda, S | 1 |
| Palani, CD | 1 |
| Beck, JF | 1 |
| Sonnemann, J | 1 |
| Mellert, HS | 1 |
| Stanek, TJ | 1 |
| Sykes, SM | 1 |
| Rauscher, FJ | 1 |
| Schultz, DC | 1 |
| McMahon, SB | 1 |
| Li, Q | 1 |
| O'Malley, ME | 1 |
| Bartlett, DL | 1 |
| Guo, ZS | 1 |
| Grinda, M | 1 |
| Clarhaut, J | 1 |
| Tranoy-Opalinski, I | 1 |
| Renoux, B | 1 |
| Monvoisin, A | 1 |
| Cronier, L | 1 |
| Papot, S | 1 |
| Knipstein, J | 1 |
| Pili, R | 2 |
| Salumbides, B | 1 |
| Zhao, M | 2 |
| Altiok, S | 1 |
| Qian, D | 1 |
| Zwiebel, J | 3 |
| Carducci, MA | 1 |
| Ungerstedt, JS | 1 |
| Sowa, Y | 1 |
| Xu, WS | 1 |
| Shao, Y | 1 |
| Dokmanovic, M | 1 |
| Perez, G | 1 |
| Ngo, L | 1 |
| Holmgren, A | 1 |
| Jiang, X | 1 |
| Marks, PA | 1 |
| Hess-Stumpp, H | 2 |
| Ryan, QC | 2 |
| Headlee, D | 1 |
| Acharya, M | 1 |
| Sparreboom, A | 3 |
| Trepel, JB | 2 |
| Ye, J | 1 |
| Figg, WD | 4 |
| Hwang, K | 3 |
| Chung, EJ | 2 |
| Murgo, A | 1 |
| Melillo, G | 2 |
| Elsayed, Y | 1 |
| Monga, M | 1 |
| Kalnitskiy, M | 2 |
| Sausville, EA | 3 |
| Acharya, MR | 2 |
| Conley, BA | 1 |
| Doroshow, JH | 2 |
| Venitz, J | 2 |
| Liu, AL | 1 |
| Long, J | 1 |
| Wang, N | 1 |
| Du, GH | 1 |
| Karp, JE | 1 |
| Ryan, Q | 1 |
| Gojo, I | 1 |
| Mnasakanyan, A | 1 |
| Hartke, C | 1 |
| Baker, SD | 1 |
| Bracker, TU | 1 |
| Henderson, D | 1 |
| Politz, O | 1 |
| Kummar, S | 1 |
| Gutierrez, M | 1 |
| Gardner, ER | 1 |
| Donovan, E | 1 |
| Lee, MJ | 1 |
| Maynard, K | 1 |
| Chen, A | 1 |
| Conley, B | 1 |
| Murgo, AJ | 1 |
| Rasheed, W | 1 |
| Bishton, M | 1 |
| Johnstone, RW | 1 |
| Prince, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Closed by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for entinostat and Benign Neoplasms
| Article | Year |
|---|---|
Histone deacetylase inhibitors: from bench to clinic.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Tria | 2008 |
HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
Topics: Animals; Benzamides; Dose-Response Relationship, Drug; Histone Deacetylase Inhibitors; Histone Deace | 2018 |
Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasms; Zi | 2022 |
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Me | 2014 |
Entinostat for treatment of solid tumors and hematologic malignancies.
Topics: Antineoplastic Agents; Benzamides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Mo | 2011 |
Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
Topics: Acetylation; Acetyltransferases; Animals; Benzamides; Clinical Trials as Topic; Gene Expression Regu | 2005 |
[A new target of cancer therapy: advances in the study of histone deacetylase].
Topics: Acetylation; Animals; Apoptosis; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Histone Acety | 2005 |
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.
Topics: Acetylation; Antineoplastic Agents; Benzamides; Gene Expression Regulation, Neoplastic; Histone Deac | 2007 |
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Depsipep | 2008 |
6 trials available for entinostat and Benign Neoplasms
| Article | Year |
|---|---|
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamide | 2015 |
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Enzyme Inhib | 2008 |
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Weste | 2012 |
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Topics: Administration, Oral; Adult; Aged; Benzamides; Drug Administration Schedule; Enzyme Inhibitors; Fema | 2005 |
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Body Mass Index; Body Su | 2006 |
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Enzyme Inhibitors; Fem | 2007 |
27 other studies available for entinostat and Benign Neoplasms
| Article | Year |
|---|---|
Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Catalytic Domain; Cell Line, Tumor; Cyc | 2011 |
The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Topics: Antineoplastic Agents; HeLa Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hyd | 2011 |
4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetyla | 2017 |
Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Design; Histone Deacetylase 1; Histone Deacetylase Inhibi | 2017 |
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Drug Design; Drug Discovery | 2021 |
Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; | 2021 |
Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia.
Topics: Animals; Benzamides; Butyric Acid; Cachexia; Cell Line, Tumor; Disease Models, Animal; Disease Progr | 2022 |
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Topics: Animals; Antigen Presentation; B7-H1 Antigen; Benzamides; Biomarkers, Tumor; CD8-Positive T-Lymphocy | 2022 |
HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity.
Topics: Antigens, Neoplasm; Benzamides; CD8-Positive T-Lymphocytes; Epitopes; Histone Deacetylase Inhibitors | 2022 |
Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles.
Topics: Animals; CD8-Positive T-Lymphocytes; Drug Delivery Systems; Immunosuppressive Agents; Ligands; Mice; | 2023 |
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Topics: Animals; Benzamides; Cell Plasticity; Cisplatin; DNA Repair; DNA Repair Enzymes; DNA-Binding Protein | 2020 |
Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Topics: Animals; Azacitidine; Benzamides; Cell Differentiation; Cell Movement; Chemotherapy, Adjuvant; Disea | 2020 |
Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors.
Topics: Animals; Benzamides; Cell Line, Tumor; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; | 2020 |
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).
Topics: Benzamides; Humans; Ipilimumab; Neoplasms; Nivolumab; Pyridines | 2021 |
Epigenetic cancer therapies emerge out of the lab into the limelight.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Resist | 2013 |
Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Proliferation | 2015 |
Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzamides; Cell Line, Tumor; Ce | 2015 |
Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells.
Topics: Apoptosis; Benzamides; Cell Cycle; Cellular Senescence; Enzyme Inhibitors; Histone Deacetylase Inhib | 2009 |
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Topics: Animals; Benzamides; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Female; Histone De | 2008 |
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Dru | 2009 |
Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Butyrate | 2012 |
Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis.
Topics: Acetylation; Apoptosis; Benzamides; Cell Line, Tumor; DNA Damage; Histone Deacetylase Inhibitors; Hu | 2011 |
Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth.
Topics: Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Movement; DNA Methylation; Epigene | 2011 |
A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dimerization; Doxorubicin; Drug | 2011 |
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
Topics: Apoptosis; Benzamides; Caspases; Cell Line, Transformed; Drug Resistance, Neoplasm; Enzyme Inhibitor | 2005 |
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Topics: Animals; Area Under Curve; Benzamides; Binding, Competitive; Blood Proteins; Dogs; Glycoproteins; Ha | 2006 |
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.
Topics: Acetates; Acetonitriles; Antineoplastic Agents; Benzamides; Butanes; Calibration; Chromatography, Hi | 2007 |